ADAGENE INC. SP.ADR Total Liabilities
ADAGENE INC. SP.ADR total liabilities. Based on the latest financial reports, ADAGENE INC. SP.ADR (978) has total liabilities worth €42.91 Million EUR (≈ $50.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ADAGENE INC. SP.ADR liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of ADAGENE INC. SP.ADR (2021–2025)
Total liabilities of ADAGENE INC. SP.ADR from 2021 to 2025. This chart illustrates how ADAGENE INC. SP.ADR's total liabilities have evolved over time, based on quarterly financial data.
ADAGENE INC. SP.ADR Competitors by Total Liabilities
The table below lists competitors of ADAGENE INC. SP.ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Savings Financial Group Inc
NASDAQ:FSFG
|
USA | $2.21 Billion |
|
Is Finansal Kiralama AS
IS:ISFIN
|
Turkey | TL77.20 Billion |
|
Hongda High-Tech Holding Co Ltd
SHE:002144
|
China | CN¥173.92 Million |
|
Shinsegae Inte
KO:031430
|
Korea | ₩567.22 Billion |
|
Neon Equity AG
XETRA:D77
|
Germany | €73.48 Million |
|
Resimac Group Ltd
AU:RMC
|
Australia | AU$16.25 Billion |
|
Huafang Co Ltd
SHG:600448
|
China | CN¥2.55 Billion |
|
RichWave Technology Corp
TW:4968
|
Taiwan | NT$854.24 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ADAGENE INC. SP.ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 978 total asset value.
Liquidity & Leverage Metrics
ADAGENE INC. SP.ADR Total Liabilities Ratios Explained
ADAGENE INC. SP.ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ADAGENE INC. SP.ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ADAGENE INC. SP.ADR (2021–2025)
The table below shows the annual total liabilities of ADAGENE INC. SP.ADR from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €42.91 Million ≈ $50.17 Million |
+10.76% |
| 2024-12-31 | €38.74 Million ≈ $45.30 Million |
-14.22% |
| 2023-12-31 | €45.17 Million ≈ $52.81 Million |
-34.83% |
| 2022-12-31 | €69.31 Million ≈ $81.03 Million |
+110.33% |
| 2021-12-31 | €32.95 Million ≈ $38.52 Million |
-- |
About ADAGENE INC. SP.ADR
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more